HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Conte, J. V. Articles by Ramwell, P. W. Search for Related Content PubMed PubMed Citation Articles by Conte, J. V., Jr Articles by Ramwell, P. W.

The Journal of Thoracic and Cardiovascular Surgery, Vol 101, 1024-1029, Copyright © 1991 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association

ARTICLES

Iron chelation therapy and lung transplantation. Effects of deferoxamine on lung preservation in canine single lung transplantation

JV Conte Jr, NM Katz, ML Foegh, RB Wallace and PW Ramwell
Department of Surgery, Georgetown University Medical Center, Washington D.C. 20007.

Reperfusion injury is a limiting factor in lung transplantation. Deferoxamine is an iron chelator that inhibits the formation of oxygen- derived free radicals. We investigated the effects of deferoxamine on posttransplantation lung function in a canine model of single lung transplantation. Twelve dogs underwent left lung transplantation after 20- to 24-hour hypothermic storage in a modified Euro-Collins solution. In six experiments donor and recipient received a 10 mg/kg dose of deferoxamine before harvest and transplantation, and 10 mg/kg was added to the preservation solution. Arterial oxygen tension, alveolar- arterial oxygen difference, pulmonary vascular resistance, and dynamic lung compliance were measured. Data were recorded for 6 hours after ligation of the native pulmonary artery. At the end of the study the mean arterial oxygen tension was 175.1 mm Hg for the deferoxamine treated group versus 71.1 mm Hg for the control group (p less than 0.001), and the alveolar-arterial oxygen difference was less in the deferoxamine-treated group: 502.3 versus 606.0 mm Hg (p less than 0.001). The mean pulmonary vascular resistance was lower throughout the study, and after 6 hours it was 455.1 dynes/sec/cm(-5) in the deferoxamine-treated group versus 663.7 dynes/sec/cm(-5) in the control group (p less than 0.035). Compliance was similar in both groups. We conclude that deferoxamine improves lung preservation and early posttransplantation function in canine single lung transplantation.

This article has been cited by other articles:

				Y. Toyoda, J. Thacker, R. Santos, D. Nguyen, J. Bhama, C. Bermudez, R. Kormos, B. Johnson, M. Crespo, J. Pilewski, et al. Long-term outcome of lung and heart-lung transplantation for idiopathic pulmonary arterial hypertension. Ann. Thorac. Surg., October 1, 2008; 86(4): 1116 - 1122. [Abstract] [Full Text] [PDF]

				R. E. Kirschner and G. A. Fantini Role of Iron in Reoxygenation Injury of Postischemic Skeletal Muscle Perspectives in Vascular Surgery and Endovascular Therapy, January 1, 1992; 5(2): 69 - 83. [PDF]